| 6.31 0.09 (1.45%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 7.56 | 1-year : | 8.84 |
| Resists | First : | 6.48 | Second : | 7.56 |
| Pivot price | 5.99 |
|||
| Supports | First : | 5.86 | Second : | 5.48 |
| MAs | MA(5) : | 5.97 |
MA(20) : | 6.01 |
| MA(100) : | 6.4  |
MA(250) : | 6.38 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 68.1 |
D(3) : | 48.4 |
| RSI | RSI(14): 58.6 |
|||
| 52-week | High : | 10.13 | Low : | 3.16 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ARDX ] has closed below upper band by 21.1%. Bollinger Bands are 36.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.44 - 6.46 | 6.46 - 6.49 |
| Low: | 6.16 - 6.18 | 6.18 - 6.21 |
| Close: | 6.26 - 6.31 | 6.31 - 6.35 |
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Sat, 14 Sep 2024
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ardelyx, - GlobeNewswire
Fri, 13 Sep 2024
Ardelyx, Inc. (NASDAQ:ARDX) CEO Michael Raab Sells 35,000 Shares - MarketBeat
Fri, 13 Sep 2024
Levi & Korsinsky Notifies Shareholders of Ardelyx, Inc.(ARDX) of a Class Action Lawsuit and an Upcoming Deadline - AccessWire
Fri, 13 Sep 2024
Los Angeles Capital Management LLC Purchases Shares of 112,325 Ardelyx, Inc. (NASDAQ:ARDX) - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 235 (M) |
| Shares Float | 230 (M) |
| Held by Insiders | 1.6 (%) |
| Held by Institutions | 61.8 (%) |
| Shares Short | 24,850 (K) |
| Shares Short P.Month | 26,560 (K) |
| EPS | -0.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.62 |
| Profit Margin | -31.1 % |
| Operating Margin | -18.7 % |
| Return on Assets (ttm) | -13.3 % |
| Return on Equity (ttm) | -48.3 % |
| Qtrly Rev. Growth | 227.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.89 |
| EBITDA (p.s.) | -0.25 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -85 (M) |
| Levered Free Cash Flow | -33 (M) |
| PE Ratio | -23.38 |
| PEG Ratio | -0.8 |
| Price to Book value | 10.17 |
| Price to Sales | 7.07 |
| Price to Cash Flow | -17.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|